Law firm investigates Nuvalent's $124/share sale to GSK for fairness to shareholders.

Monteverde & Associates PC is investigating the sale of Nuvalent, Inc. to GSK plc, where Nuvalent shareholders are set to receive $124 per share in cash. The investigation questions whether this deal is fair to shareholders. The law firm, known for recovering millions for shareholders, offers free consultation to Nuvalent stockholders concerned about the transaction. This could lead to legal action if the deal is found to be unfair or undervalued.